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Successful ventricular tachycardia ablation in a
patient with a biventricular ventricular assist device
and heparin-induced thrombocytopenia using
bivalirudinGordon Ho, MD,* Hao A. Tran, MD,* Marcus A. Urey, MD,* Eric D. Adler, MD,*
Victor G. Pretorius, MBchB,† Jonathan C. Hsu, MD, MAS, FHRS*From the *Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla,
California, and †Department of Cardiothoracic Surgery, University of California San Diego, La Jolla,
California.Introduction
Ventricular arrhythmias are common in patients with ventric-
ular assist devices.1 Ablation of ventricular tachycardia (VT)
in patients with left ventricular assist devices (LVADs) ap-
pears to be safe and effective.2–4 However, in patients with
durable biventricular assist devices (BIVAD), the safety
and feasibility of VT ablation has not been well
characterized in the literature. Only 1 case of VT ablation
has been reported in a patient with a BIVAD, in which the
right-sided inflow cannula was located in the right ventricle.5
Electroanatomic (EA) and pace mapping was performed in
the right ventricle only to guide ablation of a VT site located
near the right ventricular (RV) inflow cannula. However,
more recent implantation techniques favor implantation of
the RV assist device inflow cannula in the right atrial anterior
wall to prevent suction events frequently encountered by RV
cannulation.6,7 With this BIVAD configuration, it is
unknown whether transseptal puncture, intracardiac
echocardiography (ICE), and EA mapping can be safely
performed without encountering significant interference,
given the close proximity of electrophysiology catheters
and EA mapping patches to the inflow cannula in the right
atrium. Secondly, the safety of using bivalirudin for
anticoagulation in patients with oliguric renal failure duringKEYWORDS Anticoagulation; Biventricular assist device; Catheter ablation;
Electroanatomic mapping; Ventricular tachycardia
(Heart Rhythm Case Reports 2018;4:367–370)
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We report safe and successful VT ablation utilizing
transseptal access and bivalirudin in a patient with a
BIVAD configured with a right atrial inflow cannula.Case report
A 69-year-old man with a history of severe ischemic cardio-
myopathy presented with cardiogenic shock and underwent
BIVAD implantation with inflow cannulas (HeartWare, Fra-
mingham, MA) located in the anterior right atrial wall
(Figure 1A, red arrow) and the left ventricular (LV) apex.
His bicuspid aortic valve was partially stitched to prevent
worsening of his moderate aortic regurgitation after VAD
implantation. He had anuric renal failure and received contin-
uous renal replacement therapy. He developed heparin-
induced thrombocytopenia confirmed by serotonin release
assay and was maintained on a bivalirudin intravenous drip
at 0.09 mg/kg/h. Postoperatively, he developed unstable sus-
tained VT refractory to intravenous amiodarone, lidocaine,
and stellate ganglion pulsed radiofrequency ablation and
was referred for VT ablation.
In the electrophysiology laboratory, continuous renal
replacement therapy was temporarily stopped for the ablation
procedure. He was given multiple bivalirudin boluses of
0.3 mg/kg and his intravenous drip was eventually increased
to 0.3 mg/kg/h to achieve activated clotting time (ACT) 300–
350 s, with ACT checks every 30 minutes (Figure 2). Trans-
septal access was performed successfully per standard fashion
using a radiofrequency transseptal needle (Baylis, Montreal,
Canada), steerable long sheath (Agilis, Abbott, St. Paul,
MN), fluoroscopy, and ICE, as shown in Figure 1A. No
interference was experienced on ICE despite close proximity
of the ICE catheter (Figure 1A, white arrow) to the right atrial
inflow cannula (Figure 1A and C, red arrows).
Programmed electrical stimulation induced at least 7 VT
morphologies. However, VT morphologies would switch or
be electrically unstable, so substrate mapping was mainlyen access article
.0/).
https://doi.org/10.1016/j.hrcr.2018.05.005
KEY TEACHING POINTS
 In patients with a biventricular assist device
configured with a right atrial inflow cannula in
addition to the left ventricular inflow cannula,
ventricular tachycardia (VT) ablation may be safely
and effectively performed using standard
techniques for transseptal access, intracardiac
echocardiography (ICE), and electroanatomic (EA)
mapping.
 ICE and its integration with EA mapping is feasible
without interference from the right atrial inflow
cannula, despite close proximity of the ICE catheter
to the inflow cannula. EA mapping reference
patches should be placed as far away from
underlying inflow cannulas as possible to minimize
interference with the mapping system.
 An anticoagulation strategy utilizing bivalirudin
may be considered for patients with heparin-
induced thrombocytopenia, anuric renal failure,
and ventricular assist device hardware, but may
require titration of standard renal dosing to
maintain adequate anticoagulation for transseptal
access to the left ventricle.
368 Heart Rhythm Case Reports, Vol 4, No 8, August 2018performed (Figure 3). Electroanatomic mapping was inte-
grated with ICE (Carto 3/CartoSound, Biosense Webster,
Diamond Bar, CA), and LV geometry and a substrate mapFigure 1 Ventricular tachycardia ablation for a patient with a biventricular assi
devices implanted at the right atrial wall (red arrow) and the left ventricular apex. A
steerable sheath are in close proximity to the right atrial inflow cannula (red arrow
Electroanatomic mapping demonstrates extensive substrate ablation (round balls)
circle and mesh (yellow arrow), visualized by ICE and CartoSound (D, yellow arrwas obtained using a 3.5 mm contact force open-irrigated
ablation catheter (SmartTouch SF, Biosense Webster). The
mapping reference patches were positioned on the chest
wall in a manner to avoid overlaying the 2 inflow cannulas.
Interference was experienced with EA mapping when the
ablator was within 1 cm of the LV apical inflow cannula,
manifesting as loss of catheter visualization. No interference
was experienced with ICE integration, and the LV inflow
cannula was well visualized on ICE (Figure 1B and D).
Extensive substrate modification was performed to homoge-
nize the entire scar located circumferentially around the
entire mid-LV and sites of late potentials and fractionation.
A total of 119 lesions were delivered (Figure 1B, balls). At
the end of the procedure, VT was no longer inducible
down to ventricular effective refractory period with double
extrastimuli. Despite uninterrupted anticoagulation with bi-
valirudin, complete hemostasis was achieved using percuta-
neous sutures for all venous access sites (Perclose, Abbott,
St. Paul, MN). No complications related to the procedure
occurred. Unfortunately, although the burden of VT was
significantly reduced, the patient had 3 episodes of polymor-
phic VT 1 week later when he developed bleeding from a
gastric arteriovenous malformation that was clipped. He ulti-
mately died of sepsis and candidemia 1 month later.Discussion
Durable BIVADs utilizing 2 centrifugal VADs are increas-
ingly being used to support LVAD patients with RV failure.
More recently, a novel technique of implanting the right-
sided VAD in the right atrial anterior wall instead of the right
ventricle wall offers several advantages, such as preventingst device. A: An anteroposterior fluoroscopy image shows ventricular assist
n intracardiac echocardiography (ICE) catheter (white arrow) and transseptal
). The right atrial inflow cannula is visualized using ICE (C, red arrow). B:
with the left ventricular assist device inflow cannula denoted by the yellow
ow).
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Figure 2 Trend of activated clotting time with bivalirudin dose during
ventricular tachycardia ablation. A graph of the activated clotting time
(ACT) is plotted against time during the procedure with timing and dosing
of boluses (top) and infusion (bottom). The baseline ACT was 171 seconds
at the beginning of the case on the patient’s maintenance bivalirudin. The pa-
tient was off continuous renal replacement therapy during the case.
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There have been no reports of VT ablation in patients with
this BIVAD configuration, and it is unknown whether the
right atrial cannula may impede transseptal catheterization
or cause electromagnetic interference with catheters
typically positioned in the right atrium.
Interference in the LV has been reported with magnetic-
based mapping systems such as Carto 3 in patients with an
axial LVAD (HeartMate II, Abbott, Chicago, IL), centrifugal
LVAD (HeartWare, Medtronic), or percutaneous LV micro-
axial assist device (Impella 2.5, Abiomed, Danvers, MA).8–10
The interference is typically limited to the areas where the
ablation catheter is in close proximity to the rotational
assist device, and manifests as loss of catheter
visualization, electromagnetic interference, and/or altered
force readings. However, the interference usually has not
been significant enough to prevent successful completion
of VT ablation. Interference with the percutaneous Impella
2.5 has been noted at higher performance (P8, 50,000 rpm)Figure 3 Induced ventricular tachycardia. This surface and intracardiac electrogr
200–240) inducing a ventricular tachycardia that spontaneously changes morpholog
superior axis apical morphology.and can be reduced by temporarily turning down the
performance specifically to P6 (45,000 rpm).10 Interestingly,
interference has not been reported with purely impedance-
based mapping systems such as Velocity (Abbott, St. Paul,
MN)4 or with externally placed pumps such as VA ECMO
and TandemHeart (CardiacAssist, Pittsburgh, PA),11
although the experience with these systems has not been as
widely published.
In this case, the right atrial inflow cannula did not cause
interference with EA mapping or impede ICE or transseptal
puncture. Although loss of catheter visualization occurred
in the area immediately surrounding the LV cannula, as
reported previously,4 no interference was experienced any-
where else in the LV, and the areas around both the LV
and right atrial inflow cannulas were well visualized with
ICE and easily integrated into the EA mapping system.
This is the first report of safe and successful manipulation
of electrophysiology catheters around a right atrial inflow
cannula, and supports further studies into the feasibility of
right atrial ablation in these patients. The use of ICE near
the right atrial inflow cannula appears safe and may help
improve visualization of the areas obscured by interference
from EA mapping.
Secondly, the use of bivalirudin during catheter ablation
has only been reported in patients with normal renal function
using percutaneous coronary intervention dosing.12–14
Although this case demonstrates that bivalirudin may be
safe and effective in patients with anuric renal failure and a
BIVAD, the standard hemodialysis-adjusted dosing may
not be enough to maintain therapeutic ACT. This suggests
that in longer left-sided procedures in the setting of renal fail-
ure, it may be necessary to titrate standard renal bivalirudin
dosing to maintain adequate anticoagulation levels.Conclusion
EA mapping, ICE, and transseptal puncture are feasible and
appear safe in patients with a BIVAD with a right atrialam shows programmed electrical stimulation using double extrastimuli (400–
y from a right bundle branch block inferior axis to a left bundle branch block
370 Heart Rhythm Case Reports, Vol 4, No 8, August 2018inflow cannula. Anticoagulation with bivalirudin appears to
be safe in patients with oliguric renal failure undergoing
LV endocardial ablation via transseptal access, but may
require titration with standard laboratory monitoring in order
to assure proper anticoagulation status.Acknowledgments
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